Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd - 4th, 2021, Italy).
Autorzy:
Ascierto PA; Department of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale Tumor IRCCS 'Fondazione G. Pascale', Naples, Italy. . Agarwala SS; Hematology & Oncology, Temple University and Cancer Expert Now, Bethlehem, PA, USA. Blank C; Netherlands Cancer Institute, Amsterdam, Netherlands. Caracò C; Division of Surgery of Melanoma and Skin Cancer, Istituto Nazionale Tumori 'Fondazione Pascale' IRCCS, Naples, Italy. Carvajal RD; Division of Hematology and Oncology, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA. Ernstoff MS; Developmental Therapeutics Program, Division of Cancer Therapy & Diagnosis, NCI, Bethesda, NIHMD, USA. Ferrone S; Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. Fox BA; Earle A. Chiles Research Institute, Robert W. Franz Cancer Research Center, Providence Cancer Institute, Portland, OR, USA. Gajewski TF; Department of Pathology and Department of Medicine (Section of Hematology/Oncology), University of Chicago, Chicago, IL, USA. Garbe C; Center for Dermato-Oncology, University-Department of Dermatology, Tuebingen, Germany. Grob JJ; Dermatology Department, Hopital de La Timone, Aix-Marseille, Marseille, France. Hamid O; Medical Oncology, The Angeles Clinic and Research Institute, a Cedar-Sinai Affiliate, Los Angeles, CA, USA. Krogsgaard M; New York Grossman School of Medicine, New York University Langone, New York, NY, USA. Lo RS; Jonsson Comprehensive Cancer Center David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. Lund AW; Ronald O. Perelman Department of Dermatology, Department of Pathology, New York University Grossman School of Medicine, New York, NY, USA. Madonna G; Department of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale Tumori IRCCS 'Fondazione G. Pascale', Naples, Italy. Michielin O; Precision Oncology Center and Melanoma Clinic, Oncology Department, Lausanne University Hospital (CHUV), Lausanne, Switzerland. Neyns B; Medical Oncology, Universitair Ziekenhuis Brussel, Brussels, Belgium. Osman I; New York University Langone Medical Center, New York, NY, USA. Peters S; UNIL, Medical Oncology Department European Thoracic Oncology Platform (ETOP), Specialized Thoracic Tumor Consultation, Oncology Department UNIL CHUV Thoracic Tumor Center, Lausanne University ESMO President, Scientific Coordinator, Lausanne, Switzerland. Poulikakos PI; Department of Oncological Sciences, Department of Dermatology Icahn School of Medicine at Mount Sinai, The Tisch Cancer Institute, New York, NY, USA. QuezadaSA; Cancer Immunology Unit, Research Department of Hematology, University College London Cancer Institute, London, UK. Reinfeld B; Department of Medicine, Department of Medicine, Division of Hematology/Oncology Vanderbilt University Medical Center (VUMC), Graduate Program in Cancer Biology, Vanderbilt University, Nashville, TN, USA. Zitvogel L; Tumour Immunology and Immunotherapy of Cancer, European Academy of Tumor Immunology, Gustave Roussy, University Paris Saclay, INSERM, Villejuif Grand-Paris, France. Puzanov I; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. Thurin M; Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, NCI, Rockville, NIHMD, USA.
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 3rd-5th, 2020, Italy).
Autorzy:
Ascierto PA; Department of Melanoma, Cancer Immunotherapy and Innovative Therapy, Instituto Nazionale Tumori IRCCS 'Fondazione G. Pascale', Naples, Italy. . Blank C; Netherlands Cancer Institute, Amsterdam, The Netherlands. Dummer R; Department of Dermatology, University of Zurich Hospital, Zurich, Switzerland. Ernstoff MS; Developmental Therapeutics Program, Division of Cancer Therapy & Diagnosis, NCI, NIH, Bethesda, MD, USA. Ferrone S; Department of Surgery Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. Fox BA; Earle A. Chiles Research Institute, Robert W. Franz Cancer Center, Providence Cancer Institute, Portland, OR, USA. Gajewski TF; Department of Pathology and Department of Medicine (Section of Hematology/Oncology), University of Chicago, Chicago, IL, USA. Garbe C; Center for Dermato-Oncology, University-Department of Dermatology, Tuebingen, Germany. Hwu P; Moffitt Cancer Center, Tampa, FL, USA. Kalinski P; Cancer Vaccine and Dendritic Cell Therapies, Center for Immunotherapy, Roswell Park Comprehensive Cancer Center, Developmental Therapeutics, Buffalo, NY, USA. Krogsgaard M; Medical School, New York University Langone, New York, NY, USA. Lo RS; Jonsson Comprehensive Cancer Center David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. Luke JJ; Cancer Immunotherapeutic Center of UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA. Neyns B; Medical Oncology, Universitair Ziekenhuis Brussel, Brussels, Belgium. Postow MA; Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Weill Cornell Medical College, New York, NY, USA. QuezadaSA; Cancer Immunology Unit, Research Department of Hematology, University College London Cancer Institute, London, UK. Teng MWL; QIMR Berghofer Medical Research Institute, Herston, QLD, Australia. Trinchieri G; Laboratory of Integrative Cancer Immunology (LICI), Center for Cancer Research, NCI, NIH, Bethesda, MD, USA. Testori A; Image Rigenerative Clinic-Skin Oncology Division, Milan, Italy.; Chairman Surgical Subgroup EORTC Melanoma Group Brussels, Brussels, Belgium. Caracò C; Division of Surgery of Melanoma and Skin Cancer, Istituto Nazionale Tumori 'Fondazione Pascale' IRCCS, Naples, Italy. Osman I; New York University Langone Medical Center, New York, NY, USA. Puzanov I; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. Thurin M; Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Rockville, MD, USA.
PD-L1 signaling on human memory CD4+ T cells induces a regulatory phenotype.
Autorzy:
Fanelli G; MRC Centre for Transplantation, School of Immunology and Microbial Sciences, King's College London, Guy's Hospital, London, United Kingdom. Romano M; MRC Centre for Transplantation, School of Immunology and Microbial Sciences, King's College London, Guy's Hospital, London, United Kingdom. Nova-Lamperti E; MRC Centre for Transplantation, School of Immunology and Microbial Sciences, King's College London, Guy's Hospital, London, United Kingdom. Werner Sunderland M; Cancer Immunology Unit, University College London (UCL) Cancer Institute, London, United Kingdom. Nerviani A; Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University of London and Barts' Health NHS Trust, London, United Kingdom. Scottà C; MRC Centre for Transplantation, School of Immunology and Microbial Sciences, King's College London, Guy's Hospital, London, United Kingdom. Bombardieri M; Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University of London and Barts' Health NHS Trust, London, United Kingdom. QuezadaSA; Cancer Immunology Unit, University College London (UCL) Cancer Institute, London, United Kingdom. Sacks SH; MRC Centre for Transplantation, School of Immunology and Microbial Sciences, King's College London, Guy's Hospital, London, United Kingdom. Noelle RJ; Department of Microbiology and Immunology, Norris Cotton Cancer Center Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire, United States of America. Pitzalis C; Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University of London and Barts' Health NHS Trust, London, United Kingdom. Lechler RI; MRC Centre for Transplantation, School of Immunology and Microbial Sciences, King's College London, Guy's Hospital, London, United Kingdom.; King's Health Partners, London, United Kingdom. Lombardi G; MRC Centre for Transplantation, School of Immunology and Microbial Sciences, King's College London, Guy's Hospital, London, United Kingdom. Becker PD; MRC Centre for Transplantation, School of Immunology and Microbial Sciences, King's College London, Guy's Hospital, London, United Kingdom.
Pokaż więcej
Źródło:
PLoS biology [PLoS Biol] 2021 Apr 26; Vol. 19 (4), pp. e3001199. Date of Electronic Publication: 2021 Apr 26 (Print Publication: 2021).
Gallimore A; Division of Infection and Immunity, Cardiff University, Cardiff, UK. QuezadaSA; Cancer Immunology Unit, University College London (UCL) Cancer Institute, London, UK. Roychoudhuri R; Laboratory of Lymphocyte Signalling and Development, Babraham Institute, Cambridge, UK.
Pokaż więcej
Źródło:
Immunology [Immunology] 2019 Jul; Vol. 157 (3), pp. 187-189.
Typ publikacji:
Editorial; Introductory Journal Article; Research Support, Non-U.S. Gov't
Anti-CTLA-4 synergizes with dendritic cell-targeted vaccine to promote IL-3-dependent CD4 effector T cell infiltration into murine pancreatic tumors.
Autorzy:
Zaidi N; Laboratory of Cellular Physiology and Immunology and Chris Browne Center of Immunology and Immune Disease, The Rockefeller University, New York City, New York.; The Sidney Kimmel Comprehensive Cancer Center, The Skip Viragh Center for Pancreatic Cancer, The Bloomberg-Kimmel Institute for Cancer Immunotherapy, The Johns Hopkins University School of Medicine, Baltimore, Maryland. QuezadaSA; Research Department of Haematology, University College London Cancer Institute, London, UK. Kuroiwa JMY; Laboratory of Cellular Physiology and Immunology and Chris Browne Center of Immunology and Immune Disease, The Rockefeller University, New York City, New York. Zhang L; Laboratory of Cellular Physiology and Immunology and Chris Browne Center of Immunology and Immune Disease, The Rockefeller University, New York City, New York. Jaffee EM; The Sidney Kimmel Comprehensive Cancer Center, The Skip Viragh Center for Pancreatic Cancer, The Bloomberg-Kimmel Institute for Cancer Immunotherapy, The Johns Hopkins University School of Medicine, Baltimore, Maryland. Steinman RM; Laboratory of Cellular Physiology and Immunology and Chris Browne Center of Immunology and Immune Disease, The Rockefeller University, New York City, New York. Wang B; Laboratory of Cellular Physiology and Immunology and Chris Browne Center of Immunology and Immune Disease, The Rockefeller University, New York City, New York.
The function and dysfunction of memory CD8 T cells in tumor immunity.
Autorzy:
Reading JL; Cancer Immunology Unit, University College London Cancer Institute, University College London, London, UK.; Research Department of Haematology, University College London Cancer Institute, University College London, London, UK. Gálvez-Cancino F; Laboratory of Gene Immunotherapy, Fundación Ciencia & Vida, Santiago, Chile. Swanton C; The Francis Crick Institute, London, UK. Lladser A; Laboratory of Gene Immunotherapy, Fundación Ciencia & Vida, Santiago, Chile. Peggs KS; Cancer Immunology Unit, University College London Cancer Institute, University College London, London, UK.; Research Department of Haematology, University College London Cancer Institute, University College London, London, UK. QuezadaSA; Cancer Immunology Unit, University College London Cancer Institute, University College London, London, UK.; Research Department of Haematology, University College London Cancer Institute, University College London, London, UK.
Ghorani E; Cancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, University College London, London, UK. QuezadaSA; Cancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, University College London, London, UK. s.quezada@ucl.ac.uk.
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade.
Autorzy:
McGranahan N; The Francis Crick Institute, London WC2A 3LY, UK. Centre for Mathematics and Physics in the Life Sciences and Experimental Biology (CoMPLEX), University College London (UCL), London WC1E 6BT, UK. Cancer Research UK Lung Cancer Centre of Excellence, UCL Cancer Institute, London WC1E 6BT, UK. Furness AJ; Cancer Research UK Lung Cancer Centre of Excellence, UCL Cancer Institute, London WC1E 6BT, UK. Cancer Immunology Unit, UCL Cancer Institute, UCL, London WC1E 6BT, UK. Rosenthal R; Cancer Research UK Lung Cancer Centre of Excellence, UCL Cancer Institute, London WC1E 6BT, UK. Ramskov S; Section for Immunology and Vaccinology, National Veterinary Institute, Technical University of Denmark, 1970 Frederiksberg C, Denmark. Lyngaa R; Section for Immunology and Vaccinology, National Veterinary Institute, Technical University of Denmark, 1970 Frederiksberg C, Denmark. Saini SK; Section for Immunology and Vaccinology, National Veterinary Institute, Technical University of Denmark, 1970 Frederiksberg C, Denmark. Jamal-Hanjani M; Cancer Research UK Lung Cancer Centre of Excellence, UCL Cancer Institute, London WC1E 6BT, UK. Wilson GA; The Francis Crick Institute, London WC2A 3LY, UK. Cancer Research UK Lung Cancer Centre of Excellence, UCL Cancer Institute, London WC1E 6BT, UK. Birkbak NJ; The Francis Crick Institute, London WC2A 3LY, UK. Cancer Research UK Lung Cancer Centre of Excellence, UCL Cancer Institute, London WC1E 6BT, UK. Hiley CT; The Francis Crick Institute, London WC2A 3LY, UK. Cancer Research UK Lung Cancer Centre of Excellence, UCL Cancer Institute, London WC1E 6BT, UK. Watkins TB; The Francis Crick Institute, London WC2A 3LY, UK. Cancer Research UK Lung Cancer Centre of Excellence, UCL Cancer Institute, London WC1E 6BT, UK. Shafi S; Cancer Research UK Lung Cancer Centre of Excellence, UCL Cancer Institute, London WC1E 6BT, UK. Murugaesu N; Cancer Research UK Lung Cancer Centre of Excellence, UCL Cancer Institute, London WC1E 6BT, UK. Mitter R; The Francis Crick Institute, London WC2A 3LY, UK. Akarca AU; Cancer Immunology Unit, UCL Cancer Institute, UCL, London WC1E 6BT, UK. Department of Cellular Pathology, UCL, London WC1E 6BT, UK. Linares J; Cancer Immunology Unit, UCL Cancer Institute, UCL, London WC1E 6BT, UK. Department of Cellular Pathology, UCL, London WC1E 6BT, UK. Marafioti T; Cancer Immunology Unit, UCL Cancer Institute, UCL, London WC1E 6BT, UK. Department of Cellular Pathology, UCL, London WC1E 6BT, UK. Henry JY; Cancer Research UK Lung Cancer Centre of Excellence, UCL Cancer Institute, London WC1E 6BT, UK. Cancer Immunology Unit, UCL Cancer Institute, UCL, London WC1E 6BT, UK. Van Allen EM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA. Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA. Center for Cancer Precision Medicine, Dana-Farber Cancer Institute, Boston, MA 02215, USA. Miao D; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA. Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA. Schilling B; Department of Dermatology, University Hospital, University Duisburg-Essen, 45147 Essen, Germany. German Cancer Consortium (DKTK), 69121 Heidelberg, Germany. Schadendorf D; Department of Dermatology, University Hospital, University Duisburg-Essen, 45147 Essen, Germany. German Cancer Consortium (DKTK), 69121 Heidelberg, Germany. Garraway LA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA. Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA. Center for Cancer Precision Medicine, Dana-Farber Cancer Institute, Boston, MA 02215, USA. Makarov V; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Rizvi NA; Hematology/Oncology Division, 177 Fort Washington Avenue, Columbia University, New York, NY 10032, USA. Snyder A; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Weill Cornell Medical College, New York, NY 10065, USA. Hellmann MD; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Weill Cornell Medical College, New York, NY 10065, USA. Merghoub T; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Ludwig Collaborative Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Wolchok JD; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Weill Cornell Medical College, New York, NY 10065, USA. Ludwig Collaborative Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Shukla SA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA. Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA. Wu CJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA. Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA. Department of Medicine, Harvard Medical School, Boston, MA 02115, USA. Department of Internal Medicine, Brigham and Woman's Hospital, Boston, MA 02115, USA. Peggs KS; Cancer Research UK Lung Cancer Centre of Excellence, UCL Cancer Institute, London WC1E 6BT, UK. Cancer Immunology Unit, UCL Cancer Institute, UCL, London WC1E 6BT, UK. Chan TA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Hadrup SR; Section for Immunology and Vaccinology, National Veterinary Institute, Technical University of Denmark, 1970 Frederiksberg C, Denmark. QuezadaSA; Cancer Research UK Lung Cancer Centre of Excellence, UCL Cancer Institute, London WC1E 6BT, UK. Cancer Immunology Unit, UCL Cancer Institute, UCL, London WC1E 6BT, UK. s.quezada@ucl.ac.uk . Swanton C; The Francis Crick Institute, London WC2A 3LY, UK. Cancer Research UK Lung Cancer Centre of Excellence, UCL Cancer Institute, London WC1E 6BT, UK. s.quezada@ucl.ac.uk .
Pokaż więcej
Źródło:
Science (New York, N.Y.) [Science] 2016 Mar 25; Vol. 351 (6280), pp. 1463-9. Date of Electronic Publication: 2016 Mar 03.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
QuezadaSA; Cancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, UK. Peggs KS; Cancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, UK.
Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer.
Autorzy:
QuezadaSA; Cancer Immunology Unit, Department of Haematology, UCL Cancer Institute, Paul O'Gorman Building, 72 Huntley Street, London WC1E 6BT, UK. Peggs KS
Pokaż więcej
Źródło:
British journal of cancer [Br J Cancer] 2013 Apr 30; Vol. 108 (8), pp. 1560-5. Date of Electronic Publication: 2013 Mar 19.
Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication.
Autorzy:
QuezadaSA; Ludwig Center for Cancer Immunotherapy, Howard Hughes Medical Institute, Department of Immunology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA. Peggs KS Simpson TR Allison JP
Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies